Top Markets
Coin of the day
Galera Therapeutics, Inc. Galera Therapeutics, Inc.

Galera Therapeutics, Inc.

GRTX
Rank in Stocks #33960
Galera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical... Galera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation and commercialization of therapies aimed at revolutionizing cancer radiotherapy. Its lead investigational drug, avasopasem manganese (GC4419), functions as a small molecule superoxide dismutase mimetic. This compound has successfully completed a Phase III clinical trial targeting severe oral mucositis induced by radiation therapy in head and neck cancer (HNC) patients. Furthermore, GC4419 is currently undergoing Phase IIa clinical trials for radiotherapy-induced esophagitis in lung cancer patients, as well as for HNC patients undergoing standard-of-care radiation treatment. The company is also progressing with GC4711, another superoxide dismutase mimetic candidate, which is in a Phase I/II clinical trial. This trial evaluates its combination with stereotactic body radiation therapy (SBRT) for individuals diagnosed with non-small cell lung cancer and locally advanced pancreatic cancer. Galera Therapeutics was founded in 2012 and maintains its headquarters in Malvern, Pennsylvania.
Share Price
$17.15
Last synced: 2026-08-03
Market Cap
$6.51M
Change (1 day)
9.80%
Change (1 year)
289.77%
Country
US
Trade Galera Therapeutics, Inc. (GRTX)

Category

Stock split history for Galera Therapeutics, Inc. (GRTX)
Galera Therapeutics, Inc. stock (symbol: GRTX) underwent a total of 1 stock splits.
The most recent stock split occurred on Jul 13, 2026.
One GRTX share bought prior to Jul 13, 2026 would equal to 0.005 GRTX shares today.
Stock split list
Year Split Multiple Cumulative Multiple
2026-07-13 1:200 x0.005 x0.005
Stock splits for similar companies or competitors
Company Number of stock splits Cumulative Multiple Country
1 x2
US
0 -
NL
0 -
CH
0 -
KR
0 -
BE